Finally, the hazard of disease progression for patients with PTEN and/or PIK3CA mutated tumor biopsies was 2.02 (95% CI: 0.89–4.56; p = 0.092) times the hazard for participants with neither molecular event. This evidence concerns the gene PTEN and neoplasm.